|
1
|
Yuan X, Wang X, Gu B, Ma Y, Liu Y, Sun M,
Kong J, Sun W, Wang H, Zhou F and Gao S: Directional migration in
esophageal squamous cell carcinoma (ESCC) is epigenetically
regulated by SET nuclear oncogene, a member of the inhibitor of
histone acetyltransferase complex. Neoplasia. 19:868–884. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nakashima S, Shiozaki A, Ichikawa D,
Hikami S, Kosuga T, Konishi H, Komatsu S, Fujiwara H, Okamoto K,
Kishimoto M, et al: Transient receptor potential melastatin 7 as an
independent prognostic factor in human esophageal squamous cell
carcinoma. Anticancer Res. 37:11612017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ojiri H: Diagnostic Imaging of the
Esophageal Cancer[M]// Esophageal Squamous Cell Carcinoma.
Springer; Japan: pp. 33–61. 2015
|
|
4
|
Gallivanone F, Carne I, Interlenghi M,
D'Ambrosio D, Baldi M, Fantinato D and Castiglioni I: A method for
manufacturing oncological phantoms for the quantification of
18F-FDG PET and DW-MRI studies. Contrast Media Mol Imaging.
2017:34616842017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kirchner J, Deuschl C, Schweiger B,
Herrmann K, Forsting M, Buchbender C, Antoch G and Umutlu L:
Imaging children suffering from lymphoma: An evaluation of
different 18F-FDG PET/MRI protocols compared to
whole-body DW-MRI. Eur J Nucl Med Mol Imaging. 44:1742–1750. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Milad P, Elbegiermy M, Shokry T, Mahmoud
H, Kamal I, Taha MS and Keriakos N: The added value of pretreatment
DW MRI in characterization of salivary glands pathologies. Am J
Otolaryngol. 38:13–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weller A, Papoutsaki MV, Waterton JC,
Chiti A, Stroobants S, Kuijer J, Blackledge M, Morgan V and deSouza
NM: Diffusion-weighted (DW) MRI in lung cancers: ADC test-retest
repeatability. Eur Radiol. 27:4552–4562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hafeez S, Koh MD, Sohaib A and Huddart R:
Use of diffusion weighted-MRI (DW-MRI) as a prognostic biomarker of
survival and time to cystectomy in muscle invasive bladder cancer
(MIBC) following organ conserving treatment. Eur J Cancer.
72:S1922017. View Article : Google Scholar
|
|
9
|
Misra P, Kirpalani A, Leung G, Vlachou PA,
Lee JY, Jothy S, Zaltzman J and Yuen DA: The role of thrombectomy
and diffusion-weighted imaging with MRI in post-transplant renal
vein thrombosis: A case report. Bmc Nephrol. 18:2242017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Leber MF and Efferth T: Molecular
principles of cancer invasion and metastasis (Review). Int J Oncol.
34:881–895. 2009.PubMed/NCBI
|
|
11
|
Jiang JT, Zhang LF, Zhou B, Zhang SQ, Li
SM, Zhang W, Zhang J, Qiao Z, Kong RR, Ma YF and Chen S:
Relationships of uPA and VEGF expression in esophageal cancer and
microvascular density with tumorous invasion and metastasis. Asian
Pac J Cancer Prev. 13:3379–3383. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu J, Xia J, Zhang Y, Fu M, Gong S and
Guo Y: Associations between the expression of MTA1 and VEGF-C in
esophageal squamous cell carcinoma with lymph angiogenesis and
lymph node metastasis. Oncol Lett. 14:3275–3281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Joo K, Park SJ, Choi Y, Lee JE, Na YM,
Hong HK, Park KH, Kim HM, Chung JY and Woo SJ: Role of the Fc
Region in the Vitreous half-life of Anti-VEGF drugs. Invest
Ophthalmol Vis Sci. 58:4261–4262. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mahfouz N, Tahtouh R, Alaaeddine N, El
Hajj J, Sarkis R, Hachem R, Raad I and Hilal G: Gastrointestinal
cancer cells treatment with bevacizumab activates a VEGF
autoregulatory mechanism involving telomerase catalytic subunit
hTERT via PI3K-AKT, HIF-1α and VEGF receptors. PLoS One.
12:e01792022017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang RW, Chao YK, Wen YW, Chang HK, Tseng
CK, Chan SC and Liu YH: Predictors of pathological complete
response to neoadjuvant chemoradiotherapy for esophageal squamous
cell carcinoma. World J Surg Oncol. 12:1702014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim CK, Park BK, Lee HM, Kim SS and Kim E:
MRI techniques for prediction of local tumor progression after
high-intensity focused ultrasonic ablation of prostate cancer. Ajr
Am J Roentgenol. 190:1180–1186. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Donati F, Boraschi P, Pacciardi F,
Cervelli R, Castagna M, Urbani L, Falaschi F and Caramella D: 3T
diffusion-weighted MRI in the response assessment of colorectal
liver metastases after chemotherapy: Correlation between ADC value
and histological tumour regression grading. Eur J Radiol. 91:57–65.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bedair R, Priest AN, Patterson AJ, McLean
MA, Graves MJ, Manavaki R, Gill AB, Abeyakoon O, Griffiths JR and
Gilbert FJ: Assessment of early treatment response to neoadjuvant
chemotherapy in breast cancer using non-mono-exponential diffusion
models: A feasibility study comparing the baseline and
mid-treatment MRI examinations. Eur Radiol. 27:2726–2736. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baur A, Dietrich O and Reiser M:
Diffusion-weighted imaging of bone marrow: Current status. Eur
Radiol. 13:699–1708. 2003. View Article : Google Scholar
|
|
20
|
Tyng CJ, Guimarães MD, Bitencourt AGV,
Mattos dos Santos LC, Vieira Pinto Barbosa PN, Zurstrassen CE,
Nóbrega Pereira E, Gross JL and Chojniak R: Correlation of the ADC
values assessed by diffusion-weighted MRI and 18F-FDG
PET/CT SUV in patients with lung cancer. Applied Cancer Research.
38:92018. View Article : Google Scholar
|
|
21
|
Mahmood F, Johannesen HH, Geertsen P and
Hansen RH: Repeated diffusion MRI reveals earliest time point for
stratification of radiotherapy response in brain metastases. Phy
Med Biol. 62:2990–3009. 2017. View Article : Google Scholar
|
|
22
|
Steiger P, Barbieri S, Kruse A, Ith M and
Thoeny HC: Selection for biopsy of kidney transplant patients by
diffusion-weighted MRI. Eur Radiol. 27:4336–4344. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoshida S, Kobayashi S, Koga FJ, Ishioka
C, Ishii H, Tanaka Y, Nakanishi Y, Matsuoka N, Numao K, Saito H, et
al: The ADC value is a prognostic biomarker of upper urinary tract
cancer: Potential application to preoperative risk stratification.
Eur Urol Suppl. 12:e240–e241. 2013. View Article : Google Scholar
|
|
24
|
Pepe P, D'Urso D, Garufi A, Priolo G,
Pennisi M, Russo G, Sabini MG, Valastro LM, Galia A and Fraggetta
F: Multiparametric MRI apparent diffusion coefficient (ADC)
accuracy in diagnosing clinically significant prostate cancer.
Vivo. 31:415–418. 2017. View Article : Google Scholar
|
|
25
|
Albini A, Bruno A, Noonan DM and Mortara
L: Contribution to tumor angiogenesis from innate immune cells
within the tumor microenvironment: Implications for immunotherapy.
Front Immunol. 9:5272018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vora RA: Book review: Anti-VEGF use in
ophthalmology. Int J Retina Vitreous. 3:352017. View Article : Google Scholar
|
|
27
|
Rafii S and Lyden D: Therapeutic stem and
progenitor cell transplantation for organ vascularization and
regeneration. Nat Med. 9:702–712. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Howell KR and Armstrong J: Vascular
endothelial growth factor (VEGF) in neurodevelopmental disorders.
Curr Behavioral Neuroscience Rep. 9:1–10. 2017.
|
|
29
|
Okuda T, Tasaki T, Nakata S, Yamashita K,
Yoshioka H, Izumoto S, Kato A and Fujita M: Efficacy of combination
therapy with MET and VEGF inhibitors for MET-overexpressing
glioblastoma. Anticancer Res. 37:3871–3876. 2017.PubMed/NCBI
|
|
30
|
Koh YW, Han JH, Yoon DH, Suh C and Huh J:
PD-L1 expression correlates with VEGF and microvessel density in
patients with uniformly treated classical Hodgkin lymphoma. Ann
Hematol. 96:1833–1890. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu XL, Ling ZQ, Chen W, Xu YP and Mao WM:
The overexpression of VEGF in esophageal cancer is associated with
a more advanced TMN stage: A meta-analysis. Cancer Biomark.
13:105–113. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tae N, Lee S, Kim O, Park J, Na S and Lee
JH: Syntenin promotes VEGF-induced VEGFR2 endocytosis and
angiogenesis by increasing ephrin-B2 function in endothelial cells.
Oncotarget. 8:38886–38901. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou YL, Chen CL, Wang YX, Tong Y, Fang
XL, Li L and Wang ZY: Association between polymorphism rs11200638
in the HTRA1 gene and the response to anti-VEGF treatment of
exudative AMD: A meta-analysis. Bmc Ophthalmol. 17:972017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thulliez M, Angoulvant D, Le Lez ML, et
al: Intravitreal anti-VEGF monoclonal antibodies. Biotechnology
& Bioengineering. 106:938–951. 2014.
|
|
35
|
Olivo M: Combined use of anti-VEGF and
anti-EGFR monoclonal antibodies with photodynamic therapy
suppresses tumor growth in an in vivo tumor model. J Cancer Sci
Ther. 5:100–105. 2013.
|
|
36
|
Teng LS, Jin KT, He KF, Zhang J, Wang HH
and Cao J: Clinical applications of VEGF-trap (aflibercept) in
cancer treatment. J Chin Med Assoc. 73:449–456. 2010. View Article : Google Scholar : PubMed/NCBI
|
